Trametinib in Patients With NF1- , GNAQ- , or GNA11 -Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.
Kari B WisinskiYael FlamandMelissa A WilsonJason John LukeHussein A TawbiFangxin HongEdith P MitchellJames A ZwiebelHelen ChenRobert C GrayShuli LiLisa Meier McShaneLawrence V RubinsteinDavid R PattonP Mickey WilliamsStanley R HamiltonRobert J BehrensKathryn P PenningtonBarbara A ConleyCarlos L ArteagaLyndsay N HarrisPeter J O'DwyerAlice P ChenKeith T FlahertyPublished in: JCO precision oncology (2023)
Although these subprotocols did not meet the primary end point for ORR, significant responses or prolonged SD noted in some disease subtypes warrants further investigation.